6-[(piperidin-4-yl)amino]pyridine-3-carbonitrile | 401565-97-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-[(piperidin-4-yl)amino]pyridine-3-carbonitrile
• 英文别名: 6-(piperidin-4-ylamino)-nicotinonitrile；6-(piperidin-4-ylamino)pyridine-3-carbonitrile
• CAS: 401565-97-7
• 化学式: C₁₁H₁₄N₄
• mdl: MFCD11642834
• 分子量: 202.259
• InChiKey: VNZQNHCTEPNRGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  60.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-[(piperidin-4-yl)amino]pyridine-3-carbonitrile 、 3-(三氟甲基)溴苄 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以35%的产率得到6-[1-(3-trifluoromethyl-benzyl)-piperidin-4-ylamino]-nicotinonitrile
  参考文献：
  名称：

  WO2008/128994

  摘要：

  公开号：
• 作为产物：
  描述：

  6-氯-3-氰基吡啶 在 盐酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 6-[(piperidin-4-yl)amino]pyridine-3-carbonitrile
  参考文献：
  名称：

  PYRIDAZINONES AS PARP7 INHIBITORS

  摘要：

  本发明涉及吡啶并嗪酮和相关化合物，它们是PARP7的抑制剂，并且在癌症治疗中很有用。

  公开号：

  US20190330194A1

文献信息

• Phenyl, Pyridine, Quinoline, Isoquinoline, Naphthyridine and Pyrazine Derivatives
  申请人：Binggeli Alfred

  公开号：US20080045544A1

  公开（公告）日：2008-02-21

  This invention is concerned with compounds of the formula and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及公式的化合物及其药用盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的过程以及它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Proline derivatives and use thereof as drugs
  申请人：Kitajima Hiroshi

  公开号：US20050245538A1

  公开（公告）日：2005-11-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗效果的化合物，其作用是通过DPP-IV的抑制作用，并且作为药物产品具有令人满意的效果。本发明人发现，在丙氨酸的γ位上引入取代基的衍生物具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• Proline derivatives and the use thereof as drugs
  申请人：——

  公开号：US20040106655A1

  公开（公告）日：2004-06-03

  The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the &ggr;-position of proline represented by the formula (I) 1 wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

  本发明旨在提供具有治疗作用的化合物，由于DPP-IV抑制作用而具有满意的药物产品。本发明人发现，具有引入取代基的脯氨酸γ-位置的衍生物，其化学式为(I)1，其中每个符号如规范中所定义，具有强效的DPP-IV抑制活性，并通过增加稳定性完成了本发明。
• PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES
  申请人：Binggeli Alfred

  公开号：US20100222350A1

  公开（公告）日：2010-09-02

  This invention is concerned with compounds of the formula and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及公式及其药物可接受的盐的化合物。该发明还涉及含有这样的化合物的药物组合物，它们的制备过程以及它们用于治疗和/或预防与SST受体亚型5调节相关的疾病的用途。
• PYRIDINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS
  申请人：MacDonald Gregor James

  公开号：US20100137368A1

  公开（公告）日：2010-06-03

  The present invention relates to (1-benzyl-piperidin-4-yl)-(pyridin-2-yl)-amines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

  本发明涉及快速解离的多巴胺2受体拮抗剂(1-苄基哌啶-4-基)-(吡啶-2-基)-胺，制备这些化合物的方法，含有这些化合物作为活性成分的药物组合物。这些化合物可用于治疗或预防中枢神经系统疾病，例如精神分裂症，通过产生抗精神病作用而不产生运动副作用。